News

The pharma industry has changed dramatically in recent decades, not only in terms of the vast strides that have been made in science, but also in terms of the leadership landscape. In the 1970s, it was highly unlikely that a woman would be running one of the world’s largest pharma companies, and today we have Emma Walmsley at the helm of GlaxoSmithKline.

AMSBIO has added new experimental cell lines to its CAR T cell research range. 

Recent FDA approval of CAR T cells for treatment of leukemia and lymphoma has resulted in rapid growth in research on the therapeutic uses of such cells. The new AMSBIO experimental cell lines provide you with the power to screen antibodies and ligands against your target, enhancing your search for new CAR T therapies.

The AMR Centre has today welcomed the UK Government’s announcement of a new plan to cut inappropriate use of antibiotics and reduce drug resistant infections.


The national action plan, announced by Health Secretary Matt Hancock at the World Economic Forum in Davos, sets out how the UK will achieve its new 20 year vision for a world in which AMR is contained and controlled by 2040, covering health, animals, the environment and the food chain.

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available on the news section of the company’s website via the following link: http://arecor.com/news/

Cambridge, UK, 21 January, 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to include ex vivo T lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery, enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.

Cambridge, UK, 22 January: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed its latest patent grant in Canada. The Canadian patent is part of PredictImmune’s first family of intellectual property relating to methods for predicting autoimmune disease risk and follows successful grants in the UK and Europe in October 2018.

To view the January 2019 eNews click here


Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and healthcare sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.

CAMBRIDGE, UK, 14 January 2019 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, today announced it has appointed Stephanie Brooking as Head of Product Management. Evonetix aims to utilise its innovative silicon chip approach to deliver a high-throughput solution for the synthesis and assembly of DNA molecules with high fidelity. Stephanie will help to define the Company’s strategy for market entry and longer-term product marketing for its novel gene synthesis products.

Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).

Pages